Zogenix

GW sets its sights on Zogenix and a new Epidiolex use

A strong pivotal result should allow the company to broaden Epidiolex’s reach to tuberous sclerosis complex, as long as liver injury risk can be ruled out.

Zogenix’s pain is GW Pharma’s gain

A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.

July 12, 2018

GW’s Dravet lock looks broken as Zogenix data scores

Battle in a rare form of epilepsy queued up following positive phase III trial.

June 15, 2018

Upcoming events – Zogenix and Mallinckrodt look to rare diseases

Zogenix and Mallinckrodt face investor scrutiny as they report critical data that will answer questions about safety and efficacy.

April 19, 2018

The smoke clears for Epidiolex

February 22, 2018

GW shaky on latest setback

October 04, 2017

Big caps surge again in the third quarter

Teva's annus horribilis continues but overall the picture is bright.

September 29, 2017

Dravet hit makes Zogenix another September biotech winner

July 14, 2017

Upcoming events – Zogenix to get Dravet data while Tetraphase concentrates on IV

June 09, 2017

FDA’s move could mean Endo suffers from opioid withdrawal

August 17, 2015

KemPharm opioid project noses ahead

Load More